In Vivo Biomedical Imaging Core The In Vivo Biomedical Imaging Core provides program investigators with access to state-of-the-art in-vivo imaging resources. The core is an integral component of an institution-wide imaging center that was developed through funds provided by an NCI P20 ICMIC planning grant, the Indiana 21st Century Technology Development Fund, and the Indiana Genomics Initiative (INGEN: Funded in part by the Lilly Endowment). Matching funds to develop this program were provided by the Indiana University Radiology Associates and the Indiana University School of Medicine. In total, nearly $32M has been raised to develop this comprehensive imaging program. The core will utilize pre-clinical MRI, PET, CT, and Biolumenscence imaging systems to characterize tumor formation and growth on the basis of the biological and morphological characteristics of the tumor microenvironment. High resolution images of the structure of the eye and surrounding tissues will be generated using proton MRI for the detecting the formation of optic gliomas in Project 1. In Project 2 a broad array of molecular and structural imaging methods will be employed to identify and characterize the biology of neurofibromas. Core activities will include the development and validation of novel imaging methods as well as the provision of standardized methods for collection and analysis of image data needed to support the specific scientific objectives of projects 1 and 2.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS052606-04
Application #
7678400
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
4
Fiscal Year
2008
Total Cost
$212,904
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Bessler, Waylan K; Hudson, Farlyn Z; Zhang, Hanfang et al. (2016) Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans. Free Radic Biol Med 97:212-222
Bessler, Waylan K; Kim, Grace; Hudson, Farlyn Z et al. (2016) Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation. Hum Mol Genet 25:1129-39
Ferguson, Michael J; Rhodes, Steven D; Jiang, Li et al. (2016) Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas. Pediatr Blood Cancer 63:206-13
Stansfield, Brian K; Ingram, David A (2015) Clinical significance of monocyte heterogeneity. Clin Transl Med 4:5
Sanchez-Ortiz, Efrain; Cho, Woosung; Nazarenko, Inga et al. (2014) NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development. Genes Dev 28:2407-20
Chau, Vincent; Lim, S Kyun; Mo, Wei et al. (2014) Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res 74:586-97
Li, Fang; Downing, Brandon D; Smiley, Lucy C et al. (2014) Neurofibromin-deficient myeloid cells are critical mediators of aneurysm formation in vivo. Circulation 129:1213-24
Stansfield, Brian K; Bessler, Waylan K; Mali, Raghuveer et al. (2014) Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation. Am J Pathol 184:79-85
Staser, Karl; Park, Su-Jung; Rhodes, Steven D et al. (2013) Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. J Clin Invest 123:329-34
Staser, Karl; Shew, Matthew A; Michels, Elizabeth G et al. (2013) A Pak1-PP2A-ERM signaling axis mediates F-actin rearrangement and degranulation in mast cells. Exp Hematol 41:56-66.e2

Showing the most recent 10 out of 51 publications